CHI3L1 and neuromyelitis optica: Importantly, studies have demonstrated that blocking the CHI3L1/CRTH2/β-catenin signaling cascade can restore neurogenesis and improve cognitive outcomes [31], highlighting a potential therapeutic strategy for addressing neuroinflammatory disorders like NMO.